Antimicrobial resistance (AMR) is one of the biggest healthcare challenges of our time. Hospitals are overwhelmed by the growing demand for antibiotic susceptibility testing (AST), yet current diagnostic methods remain painfully slow. Traditional AST relies on bacterial culture steps that take 24–72 hours, delaying the right treatment. In cases like sepsis, every hour counts—delayed results mean delayed care, higher mortality, and increased healthcare costs.

We’re changing this.

Our innovative AST device uses direct-from-blood technology to bypass lengthy bacterial culture and AI algorithms to deliver accurate results in record time. This enables clinicians to choose the right antibiotic faster, reducing patient mortality and hospital stays, thus helping to fight the global spread of antimicrobial resistance.

Why we’re different:

•	Competing solutions still depend on traditional culture, limiting speed.
•	Some emerging tools skip culture but only work for urine infections — not life-threatening bloodstream infections like sepsis.
•	Our approach uniquely combines direct-from-blood testing and AI, offering the fastest and most precise solution for critical infections.

By accelerating AST for sepsis and other severe infections, we help hospitals save lives and stay ahead in the fight against AMR.

iAMRapid

Org chart

Teams

Offices

iAMRapid

Org chart

Teams

Offices

Related companies